Computational analysis of molecular basis of 1:1 interactions of NRG-1β wild-type and variants with ErbB3 and ErbB4

Authors

  • Cheng Luo,

    1. Center for Drug Discovery and Design, State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Shanghai Institutes for Biological Sciences, and Graduate School, Chinese Academy of Sciences, Shanghai, P. R. China
    Search for more papers by this author
    • C. Luo and L. Xu contributed equally to this study.

  • Lingfei Xu,

    1. Zensun (Shanghai) Science and Technology, Ltd., Shanghai, P. R. China
    Search for more papers by this author
    • C. Luo and L. Xu contributed equally to this study.

  • Suxin Zheng,

    1. Center for Drug Discovery and Design, State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Shanghai Institutes for Biological Sciences, and Graduate School, Chinese Academy of Sciences, Shanghai, P. R. China
    Search for more papers by this author
  • Xiaomin Luo,

    1. Center for Drug Discovery and Design, State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Shanghai Institutes for Biological Sciences, and Graduate School, Chinese Academy of Sciences, Shanghai, P. R. China
    Search for more papers by this author
  • Jianhua Shen,

    1. Center for Drug Discovery and Design, State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Shanghai Institutes for Biological Sciences, and Graduate School, Chinese Academy of Sciences, Shanghai, P. R. China
    Search for more papers by this author
  • Hualiang Jiang,

    Corresponding author
    1. Center for Drug Discovery and Design, State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Shanghai Institutes for Biological Sciences, and Graduate School, Chinese Academy of Sciences, Shanghai, P. R. China
    2. School of Pharmacy, East China University of Science and Technology, Shanghai, P. R. China
    • Center for Drug Discovery and Design, State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Shanghai Institutes for Biological Sciences, 555 Zu Cong Zhi Road, Shanghai 201203, P. R. China
    Search for more papers by this author
  • Xifu Liu,

    1. Zensun (Shanghai) Science and Technology, Ltd., Shanghai, P. R. China
    Search for more papers by this author
  • Mingdong Zhou

    Corresponding author
    1. Zensun (Shanghai) Science and Technology, Ltd., Shanghai, P. R. China
    • Center for Drug Discovery and Design, State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Shanghai Institutes for Biological Sciences, 555 Zu Cong Zhi Road, Shanghai 201203, P. R. China
    Search for more papers by this author

Abstract

The neuregulin/ErbB system is a growth factor/receptor cascade that has been proven to be essential in the development of the heart and the sympathetic nervous system. However, the basis of the specificity of ligand–receptor recognition remains to be elucidated. In this study, the structures of NRG-1β/ErbB3 and NRG-1β/ErbB4 complexes were modeled based on the available structures of the homologous proteins. The binding free energies of NRG-1β to ErbB3 and ErbB4 were calculated using the molecular mechanics Poisson–Boltzmann surface area (MM-PBSA) computational method. In addition, computational alanine-scanning mutagenesis was performed in the binding site of NRG-1β and the difference in the binding free energies between NRG-1β mutants and the receptors was calculated. The results specify the contribution of each residue at the interaction interfaces to the binding affinity of NRG-1β with ErbB3 and ErbB4, identifying several important interaction residue pairs that are in agreement with previously acquired experimental data. This indicates that the presented structural models of NRG-1β/ErbB3 and NRG-1β/ErbB4 complexes are reliable and could be used to guide future studies, such as performing desirable mutations on NRG-1β to increase the binding affinity and selectivity to the receptor and discovering new therapeutic agents for the treatment of heart failure. Proteins 2005. © 2005 Wiley-Liss, Inc.

Ancillary